Madrigal Pharmaceuticals ... (MDGL)
NASDAQ: MDGL
· Real-Time Price · USD
282.90
3.30 (1.18%)
At close: Jun 18, 2025, 3:59 PM
287.00
1.45%
After-hours: Jun 18, 2025, 05:56 PM EDT
1.18% (1D)
| Bid | 276 |
| Market Cap | 6.28B |
| Revenue (ttm) | 317.38M |
| Net Income (ttm) | -391.59M |
| EPS (ttm) | -17.85 |
| PE Ratio (ttm) | -15.85 |
| Forward PE | -274.02 |
| Analyst | Strong Buy |
| Ask | 290.31 |
| Volume | 220,734 |
| Avg. Volume (20D) | 329,644 |
| Open | 276.99 |
| Previous Close | 279.60 |
| Day's Range | 276.99 - 286.29 |
| 52-Week Range | 200.63 - 377.46 |
| Beta | -1.08 |
About MDGL
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol MDGL
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for MDGL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 months ago
+14.99%
Madrigal Pharmaceuticals shares are trading higher...
Unlock content with
Pro Subscription
5 months ago
-10.39%
Madrigal Pharmaceuticals shares are trading lower after the company reported preliminary Q4 and FY24 financial results.
1 month ago · seekingalpha.com
In Search Of A Tailwind, Sailing The Doldrums With Madrigal PharmaceuticalsMadrigal Pharmaceuticals' Rezdiffra for NASH achieved $137.3M in Q1 '25 sales, surpassing analyst estimates and indicating strong growth, but the stock hasn't rallied. Near-term catalysts include pote...
1 month ago · seekingalpha.com
Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2025 Earnings Call TranscriptMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL ) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Tina Ventura - Chief Investor Relations Officer Bill Sibold - Chief Executive...
